secwatch.observer — SEC 8-K summary
======================================

Issuer:     Damora Therapeutics, Inc. (DMRA)
CIK:        0001800315
Form:       8-K
Filed at:   2026-01-06T23:59:59+00:00
Accession:  0001193125-26-003490
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 3.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galecto appoints Sherwin Sattarzadeh as COO; issues warrant to Paramora
-----------------------------------------------------------------------

- Sherwin Sattarzadeh appointed COO effective Jan 5, 2026; base salary $540,000, target bonus 40%.
- Initial equity grant includes 190,376 RSUs and options for 444,209 shares vesting over four years.
- Issued warrant to Paramora for 628,302 shares at $23.01 per share under Paragon Option Agreement.
- Severance provisions: 12 months' salary (18 months if within Change in Control Period) plus accelerated vesting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800315/000119312526003490/0001193125-26-003490-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800315/000119312526003490/glto-20251231.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-003490

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer